F. Bertoni, E. Zucca, and F. Cotter, Molecular basis of mantle cell lymphoma, British Journal of Haematology, vol.10, issue.2, pp.130-140, 2004.
DOI : 10.1046/j.1365-2141.1996.5421085.x

S. Swerdlow, E. Campo, M. Seto, and H. Muller-hermelink, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Lyon: International agency for research on cancer, 2008.

M. Ghielmini and E. Zucca, How I treat mantle cell lymphoma, Blood, vol.114, issue.8, pp.1469-1476, 2009.
DOI : 10.1182/blood-2009-02-179739

W. Zhao, Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways, Leukemia, vol.32, issue.1, pp.13-21, 2009.
DOI : 10.1016/j.cellsig.2009.03.009

D. Col, J. Zancai, P. Terrin, L. Guidoboni, M. Ponzoni et al., Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma, Blood, vol.111, issue.10, pp.5142-5151, 2008.
DOI : 10.1182/blood-2007-07-103481

T. Witzig, S. Geyer, I. Ghobrial, D. Inwards, R. Fonseca et al., Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma, Journal of Clinical Oncology, vol.23, issue.23, pp.5347-5356, 2005.
DOI : 10.1200/JCO.2005.13.466

G. Hess, R. Herbrecht, J. Romaguera, G. Verhoef, M. Crump et al., Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma, Journal of Clinical Oncology, vol.27, issue.23, pp.3822-3829, 2009.
DOI : 10.1200/JCO.2008.20.7977

B. Cheson, S. Horning, B. Coiffier, M. Shipp, R. Fisher et al., Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas, Journal of Clinical Oncology, vol.17, issue.4, p.1244, 1999.
DOI : 10.1200/JCO.1999.17.4.1244

Z. Zeng, D. Sarbassov-dos, I. Samudio, K. Yee, M. Munsell et al., Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML, Blood, vol.109, issue.8, pp.3509-3512, 2007.
DOI : 10.1182/blood-2006-06-030833

D. Bufalo, D. Ciuffreda, L. Trisciuoglio, D. Desideri, M. Cognetti et al., Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus, Cancer Research, vol.66, issue.11, pp.5549-5554, 2006.
DOI : 10.1158/0008-5472.CAN-05-2825

C. Derks and D. Jacobovitz-derks, Embolic pneumopathy induced by oleic acid. A systematic morphologic study, Am J Pathol, vol.87, pp.143-158, 1977.

M. Guba, M. Yezhelyev, M. Eichhorn, G. Schmid, I. Ischenko et al., Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF, Blood, vol.105, issue.11, pp.4463-4469, 2005.
DOI : 10.1182/blood-2004-09-3540

. Wang, Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma, Journal of Hematology & Oncology, vol.3, issue.1, p.30, 2010.
DOI : 10.1186/1756-8722-3-30

URL : https://hal.archives-ouvertes.fr/inserm-00668207